Oregon Medicaid targets expensive hepatitis drug

July 31, 2014 by Jonathan J. Cooper

(AP)—An Oregon Medicaid committee is expected to significantly scale back access to an effective—but expensive—new drug used to treat hepatitis C.

The decision on Thursday would allow only a narrow set of Medicaid patients to be treated with the $1,000-per-pill drug known as Sovaldi.

Medical experts on Oregon's pharmaceutical review committee question whether the drug is worth the . Oregon's guidelines would allow the drug to be used only for patients with later stages of who have been compliant with previous medical treatments and drug-free for at least six months. The drug could only be prescribed by a liver specialist.

Oregon is grappling with the issue a day after Illinois' Medicaid program put in place tight restrictions on the use of the drug.

Explore further: FDA advisers unanimously back J&J hepatitis C drug

Related Stories

FDA advisers unanimously back J&J hepatitis C drug

October 24, 2013

An experimental hepatitis C drug from Johnson & Johnson has won unanimous support from government experts who say the medication should be approved to treat patients infected with the liver-destroying virus.

Medical groups question price of new hep C drug

March 11, 2014

An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care experts, as they consider whether it is worth the $1,000-a-pill price set by manufacturer ...

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.